A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Inclusion Criteria:
GSA2 Inclusion Criteria
Exclusion Criteria:
GSA2 Exclusion Criteria
Pittsburgh, Pennsylvania 15236, United States
Buenos Aires, Buenos Aires F.D. C1425AGC, Argentina
Kolkata, West Bengal 700020, India
Chihuahua City, Chihuahua 31110, Mexico
Mexicali, Estado de Baja California 21200, Mexico
Mexico City, Mexico City 11650, Mexico